The Future Of Cancer Care: A 50 Minute Discussion At Forbes

The future of cancer therapy, an analysis of how Immunotherapy has improved oncology outcomes for patients. This year's Forbes Summit highlighted both the difficulties, advancements and needs of the cancer care community in order to find the " cure " for cancer.
Source: Healthcare News - Category: Pharmaceuticals Authors: Tags: NYSE:MRK NASDAQ:LOXO NASDAQ:ALLO Source Type: news

Related Links:

Publication date: February 2019Source: Brain, Behavior, and Immunity, Volume 76, SupplementAuthor(s): E.G. Vichaya, D.J. Estrada, B.G. Ford, J.M. Molkentine, D.W. Vermeer, P.D. Vermeer, C.M. Taniguchi, R. DantzerWhile fatigue is one of the mostly commonly reported side effects of cancer therapy, there is significant variability in intensity and persistence of this symptom. Understanding the factors accounting for this variation may provide insight into mechanisms underlying fatigue. An often overlooked issue is the possible influence of sex differences. The few studies that have been conducted employed patient-reported out...
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
For years, cancer treatment was dominated by chemotherapy, radiation therapy, and stem cell transplantation. New insights into genetic characteristics of leukemic cells have initiated the development of the chimeric antigen receptor (CAR) T-cell therapy. This type of adoptive cell immunotherapy has been a breakthrough in the treatment of aggressive B-cell lymphoma and B-cell precursor acute lymphoblastic leukemia. In August 2018, the European Commission has approved the first CAR T-cell products – tisagenlecleucel (Kymriah®, Novartis) and axicabtagene ciloleucel (Yescarta®, Gilead) – for hematological n...
Source: Transfusion Medicine and Hemotherapy - Category: Hematology Source Type: research
In this study, CAR vectors were constructed and transfected into virus-packaging cells. Then, activated T cells were infected with retrovirus harvested from stable virus-producing single clone cell lines. CAR expression on the surfaces of the T cells was detected by flow cytometry andWestern blot. The function of CAR-T targeting EGFRvIII was then evaluated. The EGFRvIII-CAR vector was successfully constructed and confirmed by DNA sequencing. A stable virus-producing cell line was produced from a single clone by limited dilution. The culture conditions for the cell line, including cell density, temperature, and culture medi...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
sand Glioblastoma (GBM) is the most common type of primary brain tumor in adults. Despite recent advances in cancer therapy, including the breakthrough of immunotherapy, the prognosis of GBM patients remains dismal. One of the new promising ways to therapeutically tackle the immunosuppressive GBM microenvironment is the use of engineered viruses that kill tumor cells via direct oncolysis and via stimulation of antitumor immune responses. In this review, we focus on recently published results of phase I/II clinical trials with different oncolytic viruses and the new interesting findings in preclinical models. From synge...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusion: We intended to briefly summarize the current studies related to targeting the CSC antigens by cancer immunotherapy based on their properties. Moreover, we highlight that CSC antigens possess targeting activity in the treatment of cancer patients. PMID: 30714514 [PubMed - as supplied by publisher]
Source: Current Molecular Medicine - Category: Molecular Biology Authors: Tags: Curr Mol Med Source Type: research
Abstract Development of targeted cancer therapy requires a thorough understanding of mechanisms of tumorigenesis as well as mechanisms of action of therapeutics. This is challenging because by the time patients are diagnosed with cancer, early events of tumorigenesis have already taken place. Similarly, development of cancer immunotherapies is hampered by a lack of appropriate small animal models with autologous human tumor and immune system. In this article, we report the development of a mouse model of human acute myeloid leukemia (AML) with autologous immune system for studying early events of human leukemogene...
Source: Journal of Immunology - Category: Allergy & Immunology Authors: Tags: J Immunol Source Type: research
As the understanding of cancer biology expands, a wider array of treatment options has become available in the field of gynecologic cancer. Therapies that target specific molecular pathways are now being used. Drugs that target cancer angiogenesis, signal transduction, DNA repair, and immune evasion mechanisms are currently being used, in addition to or in lieu of traditional chemotherapy, to achieve more personalized treatment of each patient and their unique disease. These therapies may lead to improved survival outcomes and quality of life during treatment and during remission.
Source: Obstetrics and Gynecology Clinics - Category: OBGYN Authors: Source Type: research
AbstractImmunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the bi...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
Recent advances in cancer therapies, especially immunotherapy, have drastically impacted cancer treatment and survival. These advances engender earlier diagnosis and longer survival. Increased survivorship and novel therapies bring new challenges including symptom clusters and pain syndromes as well as unknown long-term and late effects of both disease and treatment. Assessment of symptoms as well as treatment are challenging as pharmacologic approaches must consider the treatment, interactions with treatment as well as long-term impact on the patient.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
Not all that long ago, chemotherapy was the only option to treat most advanced (metastatic) cancers. Because these drugs work by destroying rapidly dividing cells, they harm some healthy cells — such as hair follicles — as well as cancer cells. In the past two decades, cancer treatment has been transformed by targeted drugs and the emergence of chemotherapy. Targeted drugs are designed to home in on specific genes or proteins that are altered or overexpressed on cancer cells. Immunotherapy has been very successful for certain types of advanced cancers, such as lung, bladder, and skin cancers. One form of immuno...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cancer Immunotherapy Managing your health care Source Type: blogs
More News: Cancer | Cancer & Oncology | Cancer Therapy | Immunotherapy | Pharmaceuticals